Iteos Therapeutics Inc

Iteos Therapeutics — Investor Presentation (January 2022)

12 slides from Iteos Therapeutics's investor presentation, Jan 11, 2022

  1. Slide 1: Targeted Immunotherapies to Improve the Lives of People with Cancer

    Targeted Immunotherapies to Improve the Lives of People with Cancer January 2022 Nasdaq: ITOS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Wor

  3. Slide 3: iTeos Has a Unique Opportunity to Lead the Next Wave of Advances in Immuno-Oncology

    iTeos Has a Unique Opportunity to Lead the Next Wave of Advances in Immuno-Oncology Growing pipeline of candidates and combinations with the potential to improve treatment for multiple cancers Strategic collaborations targeted to effectively advance and expand our pipeline Potential best-in-class th

  4. Slide 4: Significant Progress in 2021 Setting the Groundwork for Robust Execution in 2022

    Significant Progress in 2021 Setting the Groundwork for Robust Execution in 2022 Delivered Clinical Data Data differentiating EOS-448 and inupadenant Secured Transformative Collaboration Partnership with GSK to expand and differentiate EOS-448 Progressed Clinical Development Initiated 1b/2a clinical

  5. Slide 5: iTeos is a Leader in Delivering Smart, Next-Generation Immunotherapies

    iTeos is a Leader in Delivering Smart, Next-Generation Immunotherapies We design tailored therapeutics to best harness the immune system against cancer We believe this dedication to excellence will lead to effective treatments and better outcomes for people with cancer iTeos digs deep to understand

  6. Slide 6: EOS-448 is Designed to Maximize Affinity, Potency and Activity

    EOS-448 is Designed to Maximize Affinity, Potency and Activity TIGIT is One of the Most Promising Next-Generation Immune Checkpoints EOS-448 is an Anti-TIGIT Antibody with a Multi-faceted Mechanism EOS-448 has been Selected for a Unique Epitope In Clinic, EOS-448 Induces the Proliferation of Functio

  7. Slide 7: Inupadenant is the First Adenosine Pathway Inhibitor Designed for the Treatment of Cancer

    Inupadenant is the First Adenosine Pathway Inhibitor Designed for the Treatment of Cancer Inupadenant is an Insurmountable, Highly Selective A2AR Antagonist Very High Concentration of Adenosine Found in Tumor Microenvironment CRC 262µM Potential Predictive Biomarkers Could Help to Optimize our Clini

  8. Slide 8: Differentiated Immuno-Oncology Therapeutic Candidates Rapidly Advancing Through an Expansive Development Strategy

    Differentiated Immuno-Oncology Therapeutic Candidates Rapidly Advancing Through an Expansive Development Strategy Program Regimen Indication Preclinical Phase 1 Phase 2a Randomized Registration-directed EOS-448 + dostarlimab 1L NSCLC PDL1high HNSCC Undisclosed + pembrolizumab Solid Tumors + inupaden

  9. Slide 9: EOS-448: a Differentiated FcγR-engaging anti-TIGIT Antibody

    EOS-448: a Differentiated FcγR-engaging anti-TIGIT Antibody In collaboration with GSK, a differentiated development plan ongoing in multiple combinations and indications Confirmed target engagement across all doses Leveraging derisked target to move rapidly to multiple registrational studies Regimen

  10. Slide 10: Inupadenant: the First Insurmountable Antagonist for Adenosine A2A Receptor

    Inupadenant: the First Insurmontable Antagonist for Adenosine A2A Receptor Regimen Indication Phase / Status Rationale Monotherapy Evaluating Patient and Indication Selection Biomarkers 2 / Ongoing Enhance patient and indication selection + pembrolizumab PD-1 Resistant Melanoma 2 / Ongoing Address p

  11. Slide 11: The Next Months: Significant Progress Towards our Mission to Deliver Transformative IO Therapies

    The Next 12 Months: Significant Progress Towards our Mission to Deliver Transformative IO Therapies Leverage our deep understanding of targets and our differentiated therapies to progress smart clinical strategies in the right patient populations Launch randomized and registration-directed studies i

  12. Slide 12: Immunotherapies to Improve and Extend the Lives of People Living with Cancer

    Immunotherapies to Improve and Extend the Lives of People Living with Cancer

iTeos Therapeutics — Investor Presentation (January 2022) on 6ix